| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Fulcrum Therapeutics, Inc. | Director | Stock Option (right to buy) | 36,000 | 26 Jun 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| FULC | Fulcrum Therapeutics, Inc. | 26 Jun 2025 | 1 | $0 | 4 | Director | 30 Jun 2025, 16:15 |
| FULC | Fulcrum Therapeutics, Inc. | 17 Jun 2024 | 1 | $0 | 4 | Director | 18 Jun 2024, 16:20 |
| FULC | Fulcrum Therapeutics, Inc. | 27 Jun 2023 | 1 | $0 | 4 | Director | 29 Jun 2023, 16:16 |
| FULC | Fulcrum Therapeutics, Inc. | 27 Jun 2022 | 1 | $0 | 4 | Director | 29 Jun 2022, 17:00 |
| FULC | Fulcrum Therapeutics, Inc. | 08 Dec 2021 | 1 | $0 | 4 | Director | 09 Dec 2021, 15:30 |
| FULC | Fulcrum Therapeutics, Inc. | 08 Dec 2021 | 0 | $0 | 3 | Director | 09 Dec 2021, 15:15 |